Beam TherapeuticsMEX:BEAM 68 Quick Ratio is 16.99 as of Mar. 2026, which is 197% above its 10-year median of 5.73. GuruFocus rates MEX:BEAM with a GF Score™ of 68/100 and a GF Value™ of MXN541.64 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,416 Biotechnology companies, Beam Therapeutics ranks better than 89.34% on this metric.
Beam Therapeutics has a quick ratio of 16.99. It generally indicates good short-term financial strength.
The historical rank and industry rank for Beam Therapeutics's Quick Ratio or its related term are showing as below:
MEX:BEAM'
s Quick Ratio Range Over the Past 10 Years
Min: 0.31 Med: 5.73 Max: 16.99
Current: 16.99
During the past 9 years, Beam Therapeutics's highest Quick Ratio was 16.99. The lowest was 0.31. And the median was 5.73.
MEX:BEAM's Quick Ratio is ranked better than 89.34% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs MEX:BEAM: 16.99
Beam Therapeutics (MEX:BEAM) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Beam Therapeutics Quick Ratio Related Terms
Beam Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Beam Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BEAM vs DNLI, ORKA, DYN: Quick Ratio Comparison
For the Biotechnology subindustry, Beam Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beam Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beam Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Beam Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Beam Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beam Therapeutics (MEX:BEAM) has a Quick Ratio of 16.99 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Beam Therapeutics and its competitors. This is 197% above median its historical median of 5.73. Over the past decade, Beam Therapeutics' Quick Ratio has ranged from 0.31 to 16.99. According to the industry distribution chart, Beam Therapeutics ranks #151 out of 1416 companies in the Biotechnology industry, placing it in the top 10.7%.
Is Beam Therapeutics' Quick Ratio too high?
Beam Therapeutics' current Quick Ratio of 16.99 is 197% above median its 10-year median of 5.73. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 16.99. The Biotechnology industry median Quick Ratio is 3.60. Beam Therapeutics' value of 16.99 is 371.9% above this industry median. Based on the distribution chart, Beam Therapeutics ranks #151 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Beam Therapeutics has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Quick Ratio compare to DNLI and ORKA?
According to the Biotechnology industry distribution chart, Beam Therapeutics ranks #151 out of 1416 companies for Quick Ratio. This places Beam Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Beam Therapeutics' value of 16.99 is 371.9% above this benchmark. Historically, Beam Therapeutics' own Quick Ratio has ranged from 0.31 to 16.99 over the past decade. While the company's 10-year median is 5.73 vs. the industry median of 3.60, Beam Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beam Therapeutics's current Quick Ratio of 16.99 is 371.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Beam Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beam Therapeutics's current Quick Ratio is 16.99, which is 197% above median its own 10-year median of 5.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN541.64, compared to a current price of MXN628.46 — trading 16% above its estimated fair value. The current Quick Ratio is 16.99, which is 197% above median its 10-year median of 5.73 and 371.9% above the Biotechnology industry median of 3.60. Beam Therapeutics' overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Quick Ratio is 16.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?
Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued.
The current stock price of MXN628.46 is trading 16% above its estimated GF Value™ of MXN541.64.
GuruFocus considers Beam Therapeutics to be Modestly Overvalued.
Key valuation signals for MEX:BEAM:
Quick Ratio: 16.99 (197% above median its 10-year median of 5.73)
GF Value™: MXN541.64 vs. price of MXN628.46 (16% above fair value)
Industry Position: 371.9% above the Biotechnology median (#151 of 1416)
No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
68GF Score
Get the complete analysis for MEX:BEAM
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BEAM has been successfully added to your 
